Cliff Asness's STRO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 8,605 shares of Sutro Biopharma, Inc. (STRO) worth $214,351, representing 0.00% of the portfolio. First purchased in 2020-Q4, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in STRO, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 120,633 shares. Largest reduction occurred in Q3 2025, reducing 65,827 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Sutro Biopharma (STRO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sutro Biopharma (STRO) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -9,429 | Reduce 52.28% | 8,605 | $24.91 |
| Q4 2025 | -17,411 | Reduce 49.12% | 18,034 | $11.57 |
| Q3 2025 | -65,827 | Reduce 65.00% | 35,445 | $8.68 |
| Q2 2025 | -30,820 | Reduce 23.33% | 101,272 | $7.14 |
| Q1 2025 | +120,633 | Add 1052.74% | 132,092 | $6.51 |
| Q4 2024 | -21,095 | Reduce 64.80% | 11,459 | $18.40 |
| Q3 2024 | +4,202 | Add 14.82% | 32,554 | $34.60 |
| Q2 2024 | +24,770 | Add 691.51% | 28,352 | $29.30 |
| Q1 2024 | -4,781 | Reduce 57.17% | 3,582 | $56.50 |
| Q4 2023 | +5,987 | Add 251.98% | 8,363 | $42.90 |
| Q3 2023 | -5,794 | Reduce 70.92% | 2,376 | $34.70 |
| Q2 2023 | -31,200 | Reduce 79.25% | 8,170 | $46.50 |
| Q1 2023 | +19,559 | Add 98.73% | 39,370 | $46.20 |
| Q4 2022 | +603 | Add 3.14% | 19,811 | $80.80 |
| Q3 2022 | +13,268 | Add 223.37% | 19,208 | $55.50 |
| Q2 2022 | +3,622 | Add 156.26% | 5,940 | $52.02 |
| Q1 2022 | +2,318 | New Buy | 2,318 | $82.40 |
| Q4 2021 | -1,452 | Sold Out | 0 | $0.00 |
| Q3 2021 | +1,452 | New Buy | 1,452 | $188.71 |
| Q2 2021 | -4,267 | Sold Out | 0 | $0.00 |
| Q1 2021 | +2,766 | Add 184.28% | 4,267 | $227.56 |
| Q4 2020 | +1,501 | New Buy | 1,501 | $217.19 |
Cliff Asness's Sutro Biopharma Investment FAQs
Cliff Asness first purchased Sutro Biopharma, Inc. (STRO) in Q4 2020, acquiring 1,501 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Sutro Biopharma, Inc. (STRO) for 22 quarters since Q4 2020.
Cliff Asness's largest addition to Sutro Biopharma, Inc. (STRO) was in Q1 2025, adding 132,092 shares worth $859,388.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 8,605 shares of Sutro Biopharma, Inc. (STRO), valued at approximately $214,351.
As of the Q1 2026 filing, Sutro Biopharma, Inc. (STRO) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Sutro Biopharma, Inc. (STRO) was 132,092 shares, as reported at the end of Q1 2025.